TY - JOUR
T1 - Precision drug development in ROS1-positive lung cancer
AU - Hardin, Colin
AU - Wang, Feng
AU - Cheng, Haiying
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017
Y1 - 2017
N2 - Introduction: The treatment paradigm of non-small cell lung cancer (NSCLC) continues to evolve with the advent of broadened molecularly-targeted approaches. Similar to activating EGFR mutations and ALK rearrangements, ROS1 translocations define a distinct molecular subtype of NSCLC. ROS1 forms fusion products with a series of partners, leading to oncogenesis. Areas covered: This review will discuss key ROS1-fusion related downstream pathways and diagnostic techniques for detection of ROS1 rearrangements. Crizotinib, an inhibitor of MET/ALK/ROS1, has been approved as a targeted treatment for ROS1 positive lung cancer. Moreover, we will address the main resistance mechanisms to crizotinib, including development of secondary ROS1 mutations (such as G2032R and L2026M), activation of bypass signaling pathways (including EGFR and KRAS) and limitations in central nervous system penetrance. We will also review emerging therapies in ROS1 positive NSCLC, including cabozantinib, lorlatinib, entrectinib, and ceritinib. Expert commentary: Targeted therapy in ROS1 positive NSCLC has resulted in improved clinical outcomes compared with traditional chemotherapy. Thus, it is essential to screen for ROS1 fusions in NSCLC patients. Continued investigations should focus on improving understanding and identification of resistance mechanisms upon disease progression via repeat tissue or liquid biopsy, with the ultimate goal to tailor subsequent treatment to specific aberrations.
AB - Introduction: The treatment paradigm of non-small cell lung cancer (NSCLC) continues to evolve with the advent of broadened molecularly-targeted approaches. Similar to activating EGFR mutations and ALK rearrangements, ROS1 translocations define a distinct molecular subtype of NSCLC. ROS1 forms fusion products with a series of partners, leading to oncogenesis. Areas covered: This review will discuss key ROS1-fusion related downstream pathways and diagnostic techniques for detection of ROS1 rearrangements. Crizotinib, an inhibitor of MET/ALK/ROS1, has been approved as a targeted treatment for ROS1 positive lung cancer. Moreover, we will address the main resistance mechanisms to crizotinib, including development of secondary ROS1 mutations (such as G2032R and L2026M), activation of bypass signaling pathways (including EGFR and KRAS) and limitations in central nervous system penetrance. We will also review emerging therapies in ROS1 positive NSCLC, including cabozantinib, lorlatinib, entrectinib, and ceritinib. Expert commentary: Targeted therapy in ROS1 positive NSCLC has resulted in improved clinical outcomes compared with traditional chemotherapy. Thus, it is essential to screen for ROS1 fusions in NSCLC patients. Continued investigations should focus on improving understanding and identification of resistance mechanisms upon disease progression via repeat tissue or liquid biopsy, with the ultimate goal to tailor subsequent treatment to specific aberrations.
KW - Adenocarcinoma
KW - Crizotinib
KW - Non-small cell lung cancer
KW - ROS1
KW - Resistance
UR - http://www.scopus.com/inward/record.url?scp=85054823190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054823190&partnerID=8YFLogxK
U2 - 10.1080/23808993.2017.1322899
DO - 10.1080/23808993.2017.1322899
M3 - Review article
AN - SCOPUS:85054823190
SN - 2380-8993
VL - 2
SP - 99
EP - 107
JO - Expert Review of Precision Medicine and Drug Development
JF - Expert Review of Precision Medicine and Drug Development
IS - 2
ER -